CN105051027A - 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 - Google Patents
作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 Download PDFInfo
- Publication number
- CN105051027A CN105051027A CN201480015907.3A CN201480015907A CN105051027A CN 105051027 A CN105051027 A CN 105051027A CN 201480015907 A CN201480015907 A CN 201480015907A CN 105051027 A CN105051027 A CN 105051027A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- ethoxy
- fluorophenyl
- trifluoromethyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCOc1cc(Br)cnc1* Chemical compound CCOc1cc(Br)cnc1* 0.000 description 13
- MDXJETOWOWMSCZ-UHFFFAOYSA-N C=C1C(C2NC2)=CC(c2n[nH]nn2)=CC1C(F)(F)F Chemical compound C=C1C(C2NC2)=CC(c2n[nH]nn2)=CC1C(F)(F)F MDXJETOWOWMSCZ-UHFFFAOYSA-N 0.000 description 1
- KLJLJJHZGGEDSD-ARJAWSKDSA-O CC(C)(C(F)(F)F)/C(/O)=C/C(N)=[NH2+] Chemical compound CC(C)(C(F)(F)F)/C(/O)=C/C(N)=[NH2+] KLJLJJHZGGEDSD-ARJAWSKDSA-O 0.000 description 1
- WRVDTUPCCSPFCR-RLXIPSCYSA-O CC(C)(C(F)(F)F)C(/C=C(/N)\[OH2+])=N Chemical compound CC(C)(C(F)(F)F)C(/C=C(/N)\[OH2+])=N WRVDTUPCCSPFCR-RLXIPSCYSA-O 0.000 description 1
- YHUBZKCLPILRCF-UHFFFAOYSA-N CC(C)(C)OC(C(c(c(C(F)(F)F)c1)ncc1NC)C#N)=O Chemical compound CC(C)(C)OC(C(c(c(C(F)(F)F)c1)ncc1NC)C#N)=O YHUBZKCLPILRCF-UHFFFAOYSA-N 0.000 description 1
- YOEQJXRIVMDKOM-UHFFFAOYSA-N CC(c(c(C(F)(F)F)c1)ncc1N=O)C#N Chemical compound CC(c(c(C(F)(F)F)c1)ncc1N=O)C#N YOEQJXRIVMDKOM-UHFFFAOYSA-N 0.000 description 1
- LTMFTLRZOQJNRP-UHFFFAOYSA-N CC1(C)OS(c2ccc(CC(OC)=O)c(F)c2)OC1(C)C Chemical compound CC1(C)OS(c2ccc(CC(OC)=O)c(F)c2)OC1(C)C LTMFTLRZOQJNRP-UHFFFAOYSA-N 0.000 description 1
- DHKCPXUJXBEYIP-UHFFFAOYSA-N CCCC1=CC(c2ccc(CC(Nc3ccc(CC(C)(C)CO)c(C(F)(F)F)c3)=O)cc2F)=CNC1=O Chemical compound CCCC1=CC(c2ccc(CC(Nc3ccc(CC(C)(C)CO)c(C(F)(F)F)c3)=O)cc2F)=CNC1=O DHKCPXUJXBEYIP-UHFFFAOYSA-N 0.000 description 1
- XEPCZNYKJKQIAG-UHFFFAOYSA-N CCOC(C(c1cc(F)c(CC(Nc2cnc(C(C)(C)CO)c(C(F)(F)F)c2)=O)cc1)=CN1)=CC1=O Chemical compound CCOC(C(c1cc(F)c(CC(Nc2cnc(C(C)(C)CO)c(C(F)(F)F)c2)=O)cc1)=CN1)=CC1=O XEPCZNYKJKQIAG-UHFFFAOYSA-N 0.000 description 1
- ZWTYBYLWIRPFSZ-UHFFFAOYSA-N CCOC(C(c1ccc(CC(Nc(cc2C(F)(F)F)cnc2OCCN(C)C)=O)c(F)c1)=CN1)=CC1=O Chemical compound CCOC(C(c1ccc(CC(Nc(cc2C(F)(F)F)cnc2OCCN(C)C)=O)c(F)c1)=CN1)=CC1=O ZWTYBYLWIRPFSZ-UHFFFAOYSA-N 0.000 description 1
- YDGUKGOCDBDHSY-UHFFFAOYSA-O CCOC1=CC(B2OC(C)(C)C(C)O2)=CNC1[OH2+] Chemical compound CCOC1=CC(B2OC(C)(C)C(C)O2)=CNC1[OH2+] YDGUKGOCDBDHSY-UHFFFAOYSA-O 0.000 description 1
- IAFQHMRLFASZKN-UHFFFAOYSA-N CCOC1=CC(c2cc(F)c(CC(Nc(cc3C(F)(F)F)ccc3OCCO)=O)c(F)c2)=CNC1=O Chemical compound CCOC1=CC(c2cc(F)c(CC(Nc(cc3C(F)(F)F)ccc3OCCO)=O)c(F)c2)=CNC1=O IAFQHMRLFASZKN-UHFFFAOYSA-N 0.000 description 1
- JZVWPDCTWNMSBO-UHFFFAOYSA-N CCOC1=CC(c2ccc(CC(Nc3ccc(CC(CO)(F)F)c(C(F)(F)F)c3)=O)c(F)c2)=CNC1=O Chemical compound CCOC1=CC(c2ccc(CC(Nc3ccc(CC(CO)(F)F)c(C(F)(F)F)c3)=O)c(F)c2)=CNC1=O JZVWPDCTWNMSBO-UHFFFAOYSA-N 0.000 description 1
- LNLPJHXWJXGBEV-UHFFFAOYSA-N CCc(cc1C(F)(F)F)cnc1O Chemical compound CCc(cc1C(F)(F)F)cnc1O LNLPJHXWJXGBEV-UHFFFAOYSA-N 0.000 description 1
- WWTGXYAJVXKEKL-UHFFFAOYSA-N Cc(nc1)c[n]1-c1cc(C(F)(F)F)cc(N)c1 Chemical compound Cc(nc1)c[n]1-c1cc(C(F)(F)F)cc(N)c1 WWTGXYAJVXKEKL-UHFFFAOYSA-N 0.000 description 1
- JHLCLALPGFWTGY-UHFFFAOYSA-N N#CCc(c(C(F)(F)F)c1)ncc1[N+]([O-])=O Chemical compound N#CCc(c(C(F)(F)F)c1)ncc1[N+]([O-])=O JHLCLALPGFWTGY-UHFFFAOYSA-N 0.000 description 1
- LAQFPQSYKMWFAW-UHFFFAOYSA-N N#CCc(c(F)cc(Br)c1)c1F Chemical compound N#CCc(c(F)cc(Br)c1)c1F LAQFPQSYKMWFAW-UHFFFAOYSA-N 0.000 description 1
- RCEMMXVNSKICPW-UHFFFAOYSA-N Nc1c(C[Zn])ccc(C(F)(F)F)c1N Chemical compound Nc1c(C[Zn])ccc(C(F)(F)F)c1N RCEMMXVNSKICPW-UHFFFAOYSA-N 0.000 description 1
- LSRHFWSNUFIKER-UHFFFAOYSA-N OCc(c(F)cc(Br)c1)c1F Chemical compound OCc(c(F)cc(Br)c1)c1F LSRHFWSNUFIKER-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201480015907.3A CN105051027A (zh) | 2013-03-15 | 2014-03-14 | 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013072683 | 2013-03-15 | ||
| CN2013090059 | 2013-12-20 | ||
| CN2014072449 | 2014-02-24 | ||
| CN201480015907.3A CN105051027A (zh) | 2013-03-15 | 2014-03-14 | 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 |
| PCT/IB2014/059817 WO2014141187A1 (en) | 2013-03-15 | 2014-03-14 | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105051027A true CN105051027A (zh) | 2015-11-11 |
Family
ID=50390154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480015907.3A Pending CN105051027A (zh) | 2013-03-15 | 2014-03-14 | 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 |
Country Status (33)
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109096264A (zh) * | 2018-08-28 | 2018-12-28 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
| CN110036007A (zh) * | 2016-09-29 | 2019-07-19 | 第一三共株式会社 | 吡啶化合物 |
| WO2022017524A1 (zh) * | 2020-07-23 | 2022-01-27 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
| CN115626880A (zh) * | 2022-11-15 | 2023-01-20 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
| CN115667253A (zh) * | 2020-04-27 | 2023-01-31 | 伊莱利利公司 | 可用于抑制ret激酶的化合物 |
| CN116438179A (zh) * | 2020-11-06 | 2023-07-14 | 伊莱利利公司 | 作为ret激酶抑制剂的吡唑衍生物 |
| CN116925023A (zh) * | 2023-07-18 | 2023-10-24 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| US20170283404A1 (en) * | 2014-09-08 | 2017-10-05 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
| RS58813B1 (sr) * | 2014-09-10 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) |
| MX381233B (es) | 2014-09-10 | 2025-03-12 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret). |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP3371171B1 (en) | 2015-11-02 | 2023-10-25 | Blueprint Medicines Corporation | Inhibitors of ret |
| WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| ES2904615T3 (es) | 2016-03-16 | 2022-04-05 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones al respecto |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| MX2018013885A (es) | 2016-05-13 | 2019-08-16 | Inst De Medicina Molecular Joaeo Lobo Antunes | Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3). |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JP2020519672A (ja) | 2017-05-15 | 2020-07-02 | ブループリント メディシンズ コーポレイション | ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 |
| US10093648B1 (en) * | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| TWI876442B (zh) * | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| AU2020257301B2 (en) | 2019-04-18 | 2025-10-23 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof |
| CN117903123A (zh) * | 2020-02-20 | 2024-04-19 | 广州白云山医药集团股份有限公司白云山制药总厂 | 喹啉类化合物 |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| JP2024522938A (ja) | 2021-06-03 | 2024-06-21 | フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド | 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位 |
| EP4650002A1 (en) * | 2024-05-15 | 2025-11-19 | Ludwig-Maximilians-Universität | Aniline-based modulators of the nuclear receptor tlx (nr2e1) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053476B (en) | 1999-08-12 | 2005-03-25 | Upjohn Co | 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents |
| US20040019046A1 (en) * | 2000-11-27 | 2004-01-29 | Paolo Pevarello | Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| MX2009003985A (es) * | 2006-10-16 | 2009-04-27 | Novartis Ag | Fenil-acetamidas utiles como inhibidores de cinasa de proteina. |
| EP2099774A4 (en) * | 2006-11-15 | 2010-11-24 | Ym Biosciences Australia Pty L | INHIBITORS OF KINASEACTIVITY |
| BR112012003661A2 (pt) * | 2009-08-19 | 2017-04-25 | Ambit Biosciences Corp | "compostos de biarila e métodos de uso dos mesmos." |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| AR095308A1 (es) | 2013-03-15 | 2015-10-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento |
-
2014
- 2014-03-14 AU AU2014229233A patent/AU2014229233B2/en not_active Ceased
- 2014-03-14 SI SI201430170A patent/SI2970191T1/sl unknown
- 2014-03-14 EA EA201591738A patent/EA029296B1/ru not_active IP Right Cessation
- 2014-03-14 CA CA2905627A patent/CA2905627A1/en not_active Abandoned
- 2014-03-14 BR BR112015023618A patent/BR112015023618A2/pt not_active IP Right Cessation
- 2014-03-14 PL PL14713598T patent/PL2970191T3/pl unknown
- 2014-03-14 DK DK14713598.2T patent/DK2970191T3/en active
- 2014-03-14 WO PCT/IB2014/059817 patent/WO2014141187A1/en not_active Ceased
- 2014-03-14 HR HRP20170363TT patent/HRP20170363T1/hr unknown
- 2014-03-14 TW TW103109315A patent/TW201524958A/zh unknown
- 2014-03-14 JP JP2015562529A patent/JP2016516026A/ja active Pending
- 2014-03-14 UY UY0001035465A patent/UY35465A/es unknown
- 2014-03-14 US US14/775,772 patent/US9382238B2/en not_active Expired - Fee Related
- 2014-03-14 PT PT147135982T patent/PT2970191T/pt unknown
- 2014-03-14 RS RS20170177A patent/RS55710B1/sr unknown
- 2014-03-14 SG SG11201506695UA patent/SG11201506695UA/en unknown
- 2014-03-14 NZ NZ628388A patent/NZ628388A/en not_active IP Right Cessation
- 2014-03-14 ME MEP-2017-60A patent/ME02664B/me unknown
- 2014-03-14 ES ES14713598.2T patent/ES2616655T3/es active Active
- 2014-03-14 EP EP14713598.2A patent/EP2970191B1/en active Active
- 2014-03-14 CN CN201480015907.3A patent/CN105051027A/zh active Pending
- 2014-03-14 SM SM20170152T patent/SMT201700152T1/it unknown
- 2014-03-14 PE PE2015001878A patent/PE20151538A1/es not_active Application Discontinuation
- 2014-03-14 MX MX2015012286A patent/MX2015012286A/es unknown
- 2014-03-14 LT LTEP14713598.2T patent/LT2970191T/lt unknown
- 2014-03-14 HU HUE14713598A patent/HUE033423T2/en unknown
- 2014-03-14 UA UAA201510041A patent/UA115264C2/uk unknown
-
2015
- 2015-09-03 IL IL241161A patent/IL241161A0/en unknown
- 2015-09-08 CL CL2015002514A patent/CL2015002514A1/es unknown
- 2015-09-10 PH PH12015502044A patent/PH12015502044A1/en unknown
- 2015-09-14 CR CR20150490A patent/CR20150490A/es unknown
- 2015-09-15 DO DO2015000244A patent/DOP2015000244A/es unknown
-
2016
- 2016-06-02 US US15/171,229 patent/US9789100B2/en not_active Expired - Fee Related
-
2017
- 2017-03-14 CY CY20171100319T patent/CY1118730T1/el unknown
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110036007A (zh) * | 2016-09-29 | 2019-07-19 | 第一三共株式会社 | 吡啶化合物 |
| CN110036007B (zh) * | 2016-09-29 | 2021-10-15 | 第一三共株式会社 | 吡啶化合物 |
| CN113788824A (zh) * | 2016-09-29 | 2021-12-14 | 第一三共株式会社 | 吡啶化合物 |
| CN109096264A (zh) * | 2018-08-28 | 2018-12-28 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
| CN115667253A (zh) * | 2020-04-27 | 2023-01-31 | 伊莱利利公司 | 可用于抑制ret激酶的化合物 |
| WO2022017524A1 (zh) * | 2020-07-23 | 2022-01-27 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
| TWI786742B (zh) * | 2020-07-23 | 2022-12-11 | 大陸商深圳晶泰科技有限公司 | 吡啶酮類化合物及其製備方法和應用 |
| CN115803316B (zh) * | 2020-07-23 | 2024-12-06 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
| CN115803316A (zh) * | 2020-07-23 | 2023-03-14 | 深圳晶泰科技有限公司 | 吡啶酮类化合物及其制备方法和应用 |
| CN116438179A (zh) * | 2020-11-06 | 2023-07-14 | 伊莱利利公司 | 作为ret激酶抑制剂的吡唑衍生物 |
| CN115626880B (zh) * | 2022-11-15 | 2023-11-14 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
| CN115626880A (zh) * | 2022-11-15 | 2023-01-20 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
| CN116925023A (zh) * | 2023-07-18 | 2023-10-24 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
| WO2025016082A1 (zh) * | 2023-07-18 | 2025-01-23 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105051027A (zh) | 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 | |
| CN107250110B (zh) | 作为转染重排(ret)抑制剂的新化合物 | |
| JP6763919B2 (ja) | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 | |
| KR102153886B1 (ko) | Atr 키나제 억제제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물, 이의 제조 방법, 이의 상이한 고체형 및 방사성표지된 유도체 | |
| CN117062816A (zh) | 三环-酰胺-双环prmt5抑制剂 | |
| CN109563043B (zh) | 作为dnmt1的抑制剂的取代的吡啶 | |
| TWI683807B (zh) | 作為轉染重排（ｒｅｔ）抑制劑之新穎化合物 | |
| JP5889875B2 (ja) | アザインダゾール | |
| KR101914321B1 (ko) | 아릴- 또는 헤테로아릴-치환된 벤젠 화합물 | |
| CN104220070B (zh) | 谷氨酰胺酶的杂环抑制剂 | |
| US8937071B2 (en) | Compounds as rearranged during transfection (RET) inhibitors | |
| CN115811976A (zh) | 使用myt1抑制剂的方法 | |
| CN104968646B (zh) | Zeste同源物增强子2的抑制剂 | |
| TW201922721A (zh) | 化學化合物 | |
| CN105980386A (zh) | 吡唑并化合物及其用途 | |
| CN102470127A (zh) | 联芳基化合物和其使用方法 | |
| JP2021519308A (ja) | 転写活性化タンパク質のイミダゾピペラジン阻害剤 | |
| TW202448473A (zh) | 包含ｓｏｓ１抑制劑及抗癌藥物的用於治療癌症之藥學組成物 | |
| WO2021136354A1 (zh) | 联苯类衍生物抑制剂、其制备方法和应用 | |
| KR102866724B1 (ko) | 아자헤테로아릴 화합물 및 이의 용도 | |
| TW201927787A (zh) | 吡咯並三嗪化合物及抑制ｔａｍ激酶之方法 | |
| WO2020192570A1 (zh) | 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 | |
| CN110099899B (zh) | 用作irak抑制剂的噁唑衍生物及其制备方法 | |
| WO2024199524A1 (zh) | 作为pkmyt1抑制剂的化合物 | |
| HK40037519B (zh) | Ptpn11的取代的杂环抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20180622 |
|
| AD01 | Patent right deemed abandoned |